BRD9 and ovarian cancer: In our study, we found that overexpression of BRD9 rendered ovarian cancer cells resistant to PARP inhibitors and platinum, while depletion of BRD9 made cells sensitive to chemotherapy, suggesting that BRD9 related ovarian cancer chemoresistance, and identifying BRD9 as a potential drug target in ovarian cancer.